Ascentage Pharma Group International (NASDAQ:AAPG) Reaches New 12-Month Low – What’s Next?

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG)’s share price reached a new 52-week low on Friday . The stock traded as low as $19.11 and last traded at $19.5410, with a volume of 18427 shares changing hands. The stock had previously closed at $20.18.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on AAPG shares. China Intl Cap raised Ascentage Pharma Group International to a “strong-buy” rating in a report on Monday, April 6th. BTIG Research reissued a “buy” rating and issued a $48.00 target price on shares of Ascentage Pharma Group International in a report on Monday, April 13th. Finally, Deutsche Bank Aktiengesellschaft started coverage on Ascentage Pharma Group International in a report on Friday, April 24th. They issued a “buy” rating and a $40.00 target price for the company. Two investment analysts have rated the stock with a Strong Buy rating and six have given a Buy rating to the company’s stock. Based on data from MarketBeat, Ascentage Pharma Group International presently has a consensus rating of “Buy” and an average target price of $46.67.

Ascentage Pharma Group International Stock Performance

The company has a 50-day moving average of $23.88 and a 200-day moving average of $26.74. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.79 and a quick ratio of 1.77.

Ascentage Pharma Group International (NASDAQ:AAPG) last issued its quarterly earnings results on Wednesday, March 25th. The company reported ($0.52) earnings per share (EPS) for the quarter. The company had revenue of $24.72 million during the quarter. As a group, equities research analysts forecast that Ascentage Pharma Group International – Unsponsored ADR will post -1.09 EPS for the current fiscal year.

Hedge Funds Weigh In On Ascentage Pharma Group International

Several institutional investors have recently added to or reduced their stakes in AAPG. Hsbc Holdings PLC acquired a new position in Ascentage Pharma Group International in the 2nd quarter valued at about $391,000. Mirae Asset Global Investments Co. Ltd. acquired a new position in Ascentage Pharma Group International during the 3rd quarter worth approximately $96,000. ABC Arbitrage SA acquired a new position in Ascentage Pharma Group International during the 3rd quarter worth approximately $204,000. UBS Group AG increased its position in Ascentage Pharma Group International by 149.4% during the 3rd quarter. UBS Group AG now owns 18,345 shares of the company’s stock worth $716,000 after purchasing an additional 10,988 shares during the period. Finally, XY Capital Ltd increased its position in Ascentage Pharma Group International by 224.2% during the 3rd quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock worth $707,000 after purchasing an additional 12,530 shares during the period.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.